Retrospective analysis demonstrates enhanced mortality risk stratification using the SCAI-V classification after cardiac arrest, suggesting improved selection for early invasive therapies.
BACKGROUND: Classifying cardiogenic shock (CS) after out-of-hospital cardiac arrest (OHCA) is challenging, with end-organ hypoperfusion arising from mechanisms distinct to non-arrested CS. AIMS: We sought to evaluate the performance of current CS classifications and to develop the Society for Cardiovascular Angiography and Interventions (SCAI)-V classification of CS after resuscitated OHCA. METHODS: We performed a retrospective analysis of an international derivation cohort (London, United Kingdom; GdaÅsk, Poland; n=627) and external validation of the 2x2 SCAI-V construct in the TTM-2 trial cohort (n=1,781). The primary outcome was mortality; the secondary outcome was non-neurological mortality at hospital discharge (derivation cohort) or at 180 days (TTM-2 cohort). RESULTS: In the derivation cohort, the median age was 63 years (interquartile range 53-74), and 76% were male. Applying the 2022 SCAI classification (SCAI-2022), 60% of patients had discordant haemodynamic parameters and lactate levels. We developed the SCAI-V classification, grouping patients according to their SCAI grade (shock absent or present) and lactate level (<5 mmol/L or ≥5 mmol/L) into four phenotypes - non-shock, systemic ischaemia, haemodynamic shock, and haemometabolic shock - using a 2x2 factorial framework. The SCAI-V classification was associated with all-cause and non-neurological mortality (p<0.001). Survival was highest in the non-shock group (78% and 68%, in the derivation and validation cohorts, respectively), followed by haemodynamic shock (60% and 51%), then systemic ischaemia (50% and 42%), and lowest in the haemometabolic group (20% and 27%). In the derivation cohort, the SCAI-V classification displayed superior model fit, discrimination, and calibration than the 2019 and 2022 SCAI classifications. In the TTM-2 cohort, external evaluation using SCAI-V showed consistent model fit advantages and discrimination comparable to SCAI-2022. CONCLUSIONS: The SCAI-V classification enhances phenotypic profiling of CS after resuscitated OHCA and may improve patient selection for early invasive therapies in this population.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: